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Mitochondrial ﬁssionAMP-activated protein kinase (AMPK) is a key cellular energy sensor and regulator of metabolic homeostasis.
Although it is best known for its effects on carbohydrate and lipid metabolism, AMPK is implicated in diverse
cellular processes, including mitochondrial biogenesis, autophagy, and cell growth and proliferation. To further
our understanding of energy homeostasis through AMPK-dependent processes, the design and application of
approaches to identify and characterise novel AMPK substrates are invaluable. Here, we report an afﬁnity
proteomicstrategy for the discovery and validation of AMPK targets using an antibody to isolate proteins
containing the phospho-AMPK substrate recognitionmotif fromhepatocytes that had been treatedwith pharma-
cological AMPK activators. We identiﬁed 57 proteins that were uniquely enriched in the activator-treated
hepatocytes, but were absent in hepatocytes lacking AMPK. We focused on two candidates, cingulin and mito-
chondrial ﬁssion factor (MFF), and further characterised/validated them as AMPK-dependent targets by immu-
noblotting with phosphorylation site-speciﬁc antibodies. A small-molecule AMPK activator caused transient
phosphorylation of endogenous cingulin at S137 in intestinal Caco2 cells. Multiple splice-variants of MFF appear
to express in hepatocytes andwe identiﬁed a common AMPK-dependent phospho-site (S129) in all the 3 predom-
inant variants spanning the mass range and a short variant-speciﬁc site (S146). Collectively, our proteomic-based
approach using a phospho-AMPK substrate antibody in combination with genetic models and selective AMPK
activators will provide a powerful and reliable platform for identifying novel AMPK-dependent cellular targets.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Maintaining the balance of ATP-generating andATP-consumingpro-
cesses is a fundamental component of cellular energy homeostasis.
AMP-activated protein kinase (AMPK) is a central energy/nutriente; ACC, acetyl-CoA carboxylase;
C1D1, TBC1 (tre-2/USP6, BUB2,
iences SA, EPFL Innovation Park,
6133; fax: +41 216326499.
oto).
k, Warrington WA1 1RX, UK.
. This is an open access article undersensor of adenine nucleotide levels that is stimulatedwhen cells/tissues
are exposed to metabolic stresses (e.g. hypoxia, ischaemia) that lower
cellular energy status by decreasing the catabolic generation of ATP or
by promoting ATP consumption (e.g. muscle contraction). In response,
AMPK functions to restore energy homeostasis by slowing the rate of
anabolic pathways andother ATP-consumingprocesseswhile accelerat-
ing ATP-producing catabolic pathways.
AMPK is a heterotrimer comprising a catalyticα subunit and regula-
tory β and γ subunits.Multiple isoforms encoded by distinct genes exist
(α1, α2; β1, β2; γ1, γ2, γ3), which can form multiple distinct
heterotrimeric combinations [1,2]. The γ subunits contain four tandem
cystathionine β-synthase (CBS) repeats that impart adenine nucleotide
binding. AMPK activity increases upon phosphorylation of a conservedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and/or AMP induces conformational changes that promote net T172
phosphorylation by (1) the enhancement of T172 phosphorylation
and (2) the suppression of T172 dephosphorylation [3–5]. In addition,
the binding of AMP (but not ADP) further increases AMPK activity by
direct allosteric activation [3]. The major upstream kinase phosphory-
lating T172 in most mammalian cells is a complex containing LKB1,
which itself seems to be constitutively active [6,7]. In some cellular
environs, T172 can be phosphorylated in a Ca2+-mediated process
catalysed by Ca2+/calmodulin-dependent protein kinase kinases
[1,2].
AMPK is considered an important future target for drugs to treat
metabolic disorders, as AMPK activation brings about metabolic
responses desirable to counteract themetabolic abnormalities associated
with obesity, insulin resistance, and type 2 diabetes. For instance, AMPK
phosphorylates and inactivates acetyl-CoA carboxylase-1 (ACC1) and 3-
hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), key enzymes of
fatty acid and sterol biosynthesis, respectively. Moreover, previous stud-
ies have demonstrated that the activation of AMPK promotes fatty acid
oxidation through phosphorylation of acetyl-CoA carboxylase-2 (ACC2)
and glucose uptake in skeletal muscle involving phosphorylation of
TBC1D1 [1,2,8–11].
Although it is best known for its effects on metabolism, AMPK is
implicated in many other processes, including mitochondrial bio-
genesis and disposal, autophagy, cell polarity, and cell growth and
proliferation [12]. To deepen our understanding of cellular energy
homeostasis through AMPK-dependent processes, development
and application of approaches to identify novel AMPK substrates
are important. Previous studies have elucidated the AMPK recogni-
tion motif by employing multiple approaches, including synthetic
peptides [13], site-directed mutagenesis with a recombinant sub-
strate and molecular modelling [14,15], and more recently a peptide
library approach [16]. AMPK phosphorylates sites that have at least
one basic side chain (usually R, but can be K or H) either four or
three residues N-terminal with respect to the phospho-acceptor
site (S or T). It also requires hydrophobic side chains at−5 and +4
(usually L or M, but I, V or F in some cases) [12]. We sought to take
advantage of this established AMPK substrate motif by utilising an anti-
body raised against a degenerate peptide library containing ﬁxed leu-
cine and arginine residues at the−5 and−3 positions N-terminal to
the phospho-acceptor (S/T) residue to immunoprecipitate and identify
potential AMPK substrates by mass spectrometry (MS). Here we report
a list of potential cellular AMPK targets and validation/biochemical
characterisation of two selected hits, cingulin andmitochondrial ﬁssion
factor (MFF).2. Materials and methods
2.1. Materials
Materials used include λ-phosphatase (P0753; New England
Biolabs), 5-aminoimidazole-4-carboxamide riboside (AICAR, A611700;
Toronto Research Chemicals), mass spectrometry grade trypsin
(V528A; Promega), Protein G Sepharose (P3296; Sigma), FLAG-M2
resin (A2220; Sigma) and NHS-activated Sepharose (17-0906-01; GE
Healthcare). A769662 was synthesized as described previously [17] or
obtained from Selleck Chemicals (S2697). 991 (5-[[6-chloro-5-(1-
methylindol-5-yl)-1H-benzimidazol-2-yl]oxy]-2-methyl-benzoic acid)
(CAS#: 129739-36-2) was synthesized by Spirochem. COS-1 (CRL-
1650) and Caco2 (HTB-37) cell lines were obtained from ATCC. General
and speciﬁc cell culture reagents, including Williams' medium E, were
obtained from Life Technologies. Formic acid (FA, 99%) and acetonitrile
were from BDH. Water (18.2 MΩ·cm at 25 °C) was obtained from a
Milli-Q apparatus (Millipore). All othermaterials unless otherwise indi-
cated were from Sigma.2.2. Antibodies
Total acetyl-CoA carboxylase (ACC; #3676), phospho-ACC1 (S79;
#3661), total Raptor (#2280), phospho-Raptor (S792; #2083), total
AMPKα (#2532), phospho-AMPKα (T172; #2535), total p70 S6 kinase
(p70S6K; #2708) and phospho-p70S6K (T389; #9234) and phospho-
(S/T) AMPK substrate motif (#5759, lot #4) antibodies were from
Cell Signaling Technology. Total mitochondrial ﬁssion factor (MFF)
antibodies were from Proteintech (17090-1-AP) and Santa Cruz
Biotechnology (sc-168593). Total cingulin antibodies were from
Proteintech (21369-1-AP) and Santa Cruz Biotechnology (sc-365264).
The antibodies against α-tubulin (T6074) and FLAG (F7425) were
from Sigma. Horseradish peroxidase-conjugated secondary antibodies
were from Jackson ImmunoResearch Europe. Site-speciﬁc rabbit
polyclonal antibodies against phospho-MFF and phospho-cingulin
were generated by YenZym Antibodies (South San Francisco, CA,
USA) by immunisation with a phosphorylated peptide of the human
sequence (CRLKRER-*S-MSENAVR-amide for pS129 MFF, CKRERSM-
*S-ENAVRQN-amide for pS131 MFF, CGQLVRND-*S-MYGISN-amide for
pS146 MFF and the preﬁx * denotes the phosphorylated residue) or
a combination of two phosphorylated peptides of the human and
mouse sequences (CKLLRSH-*S-QASLAGP-amide and CKLIRSQ-*S-
QASLTGL-amide for pS137 cingulin).
2.3. Animals
Wild-typemale C57BL/6micewere obtained from Jackson Laborato-
ries. All protocols for animal use and euthanasia were approved by the
McMaster University Animal Research Ethics Board. Generation of
liver-speciﬁc AMPKα1/α2 knockout mice has been described previ-
ously [18]. Experiments using AMPKα1/α2 double knockout and its
control mice were performed under the approval of the ethics com-
mittee from University Paris Descartes (no. CEEA34.BV.157.12) and
the French authorisation to experiment on vertebrates (no. 75-886) in
accordance with the European guidelines.
2.4. Cloning and mutagenesis
The coding regions of cDNAs of interest were generated using the
GoTaq 1-step PCR system (Promega). Human cingulin (NM_020770.2)
was ampliﬁed from human pancreas RNA (Agilent, 540023). Mouse
MFF ampliﬁcation primers were designed based on sequence NM_
029409.2 (Forward primer: 5′-GGATCCATGGCAGAAATTAGTCGAATTC
AGTA-3′, reverse primer: 5′-CTAGCGTCGAAACCAGAGCCAGCTGT-3′).
RNA from 5 different mouse tissues (brain, 736001; heart, 736005; kid-
ney, 736007; liver, 736009; and testis, 736023; all from Agilent) was
used as a template. The resulting PCR products were ligated into inter-
mediate vectors using Strataclone PCR cloning kit (Agilent). Site-
directed mutagenesis was performed according to the QuikChange
method (Stratagene) using KOD polymerase (Novagen). The sequences
of all the clones have been veriﬁed utilising the BigDye Terminator 3.1
kit and 3500XL Genetic analyzer (Applied Biosystems) in-house at Nes-
tlé Institute of Health Sciences.
2.5. General cell culture and mouse primary hepatocytes
Caco2 cells were cultured in DMEM supplemented with 15% foetal
calf serum and 1× MEM non-essential amino acids. Experiments were
performed on cells cultured for 2 days after reaching conﬂuence. COS-
1 cells were cultured in DMEM supplemented with 10% foetal calf
serum. Cells were transfected with DNA using polyethylenimine,
treated and harvested 36 h post-transfection. Cells were washed
with ice-cold PBS and scraped into lysis buffer (50 mM tris pH 7.5,
1 mM EDTA, 1 mM EGTA, 0.27 M sucrose, 1% (w/v) Triton X-100,
20 mM glycerol-2-phosphate, 50 mM NaF, 5 mM sodium pyrophos-
phate, 0.5 mM PMSF, 1 mM benzamidine, 1 mM dithiothreitol, 1 mM
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and cultured as previously described [18–20]. Cells were treated with
orwithout AICAR and A769662 as indicated in ﬁgure legends. Following
the treatment, media were aspirated and cells lysed on ice in cold lysis
buffer containing 1% complete protease inhibitor cocktail (Roche).
Lysates were snap-frozen in liquid nitrogen and stored at−80 °C for
subsequent analyses. Lysates were clariﬁed at 3500 g for 15 min at
4 °C and normalised using Bradford reagent and BSA as standard.
2.6. Immunoprecipitation, phosphatase treatment and immunoblotting
For immunoprecipitation, lysates were incubated with 1 μg of
antibody and 5 μl of Protein G Sepharose or 5 μl FLAG-M2 resin on a
vibrating platform shaker (1000 rpm) for 2 h at 4 °C. For immunoprecip-
itation of MFF from cell extracts, the antibody was cross-linked to NHS-
activated Sepharose according to the manufacturer's instructions.
Dephosphorylation of overexpressed protein was performed as previ-
ously described [21]. Brieﬂy, FLAG-MFF was immunoprecipitated
using FLAG-M2 resin and dephosphorylated using λ-phosphatase for
30min at 30 °C. Dephosphorylation reactionswere terminated by dena-
turation in Laemmli buffer and samples were separated by SDS-PAGE,
and transferred to nitrocellulose membrane. Membranes were blocked
for 1 h in 20 mM tris (pH 7.6), 137 mM NaCl, 0.1% (v/v) Tween-20
(TBST) containing 5% (w/v) skimmedmilk. Membranes were incubated
in primary antibody prepared in TBST containing 1% (w/v) BSA over-
night at 4 °C. Detection was performed using horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence
reagent.
2.7. Trypsin digestion and MS analysis
Immunoprecipitated proteins from hepatocyte lysates (2 mg) were
denatured in Laemmli buffer, alkylated using iodoacetamide and sepa-
rated by SDS-PAGE on NuPAGE 4–12% bis-tris gels (Life Technologies).
Gels were stained with colloidal Coomassie and regions of interest
were excised. Gel pieces were destained by successive washing
(10 min, 30 °C) in water, 50% acetonitrile, 0.1 M triethylammonium
bicarbonate (TEAB, pH 8.5) and 50 mM TEAB in 50% acetonitrile. Gel
pieces were dehydrated in 100% acetonitrile and dried by Speedvac
before rehydration in 25mMTEAB containing 5 μg/ml trypsin overnight
(30 °C). The peptide digestion products were then extracted sequen-
tially with one volume of 100% acetonitrile (15 min, 30 °C) and one
volume of 25% acetonitrile and 1.25% formic acid (15 min, 30 °C). The
resulting supernatants were pooled and evaporated. Dried peptides
were redissolved in 5% acetonitrile/0.25% formic acid. Reversed-phase
liquid chromatography tandem MS (RPLC-MS/MS) analysis was
performed on a LTQ-Orbitrap Velos coupled to a Proxeon Easy-LC.
The peptide mixtures were loaded onto a C18 guard column (1.9 μm;
0.1 × 20 mm) and separated on a C18 in-house packed emitter
(1.9 μm; 0.075 × 150 mm) over a 55 min linear gradient (5% to 45% B.
A: 2% acetonitrile 0.1% formic acid B: 80% acetonitrile 0.1% formic
acid). The Orbitrap was set to analyse the survey scans (m/z 350 to
1600) at 60,000 resolution and the top 10 ions in each duty cycle
were selected for MS/MS in the LTQ linear ion trap with collision-
induced dissociation (CID) (normalised collision energy (NCE) 36%).
The data was searched against the Swiss-Prot database (26/01/2014 re-
lease) restricted toMus musculus (16656 entries) using Mascot (2.4.1).
AllMascot resultﬁleswere loaded into Scaffold (4.3.4). Peptide and pro-
tein thresholds were set to 95.0% with a 2 unique peptide criterion to
report protein identiﬁcation.
For analysis ofMFF sites phosphorylated in vivo, dried peptideswere
dissolved in 3% acetonitrile/0.1% formic acid. RPLC-MS/MS analysis was
performed on a LTQ-Orbitrap Elite equipped with an Ultimate 3000
RSLC nano system. The analytical separation was run for 70 min using
an Acclaim PepMap RSLC 75 μm × 50 cm (C18, 2 μm, 100 Å) column.
For survey scans, the Orbitrap resolution was 120,000 with an m/zwindow from 300 to 1500. The top 20 precursor ions were selected
for MS/MS in the LTQ with CID (NCE 30%). The data was searched
against the Q6PCP5-4|MFF_MOUSE sequence from Swiss-Prot (07/03/
2014 release) using Mascot (2.4.0). All Mascot result ﬁles were loaded
into Scaffold (4.3.2). Peptide and protein thresholds were 95.0% and
99.0% respectively with a 2 unique peptide criterion.
3. Results
3.1. Immunoprecipitation and identiﬁcation of AMPK-regulated/
phosphorylated proteins in hepatocytes utilising the phospho-AMPK
substrate motif antibody and MS
Mouse primary hepatocytes were treated with a combination of
two pharmacological AMPK activators, AICAR (0.3 mM) and A769662
(10 μM), which causes an acute and robust activation of AMPK com-
pared to single compound treatment [18,21]. Immunoblot analysis of
total cell extracts conﬁrmed a potent activation of AMPK in the
compound-treated samples, as phosphorylation of AMPKα within the
activation loop (T172) as well as phosphorylation of known bona ﬁde
AMPK substrates (ACC and Raptor) was markedly increased (Fig. 1A).
We also observed that the treated samples showed a robust inhibition
of p70S6K phosphorylation (T389), a well characterised consequence
of AMPK activation due to suppression of mTOR complex 1 by phos-
phorylation of Raptor and tuberous sclerosis 2 (TSC2 (also known
as tuberin)) [1] (Fig. 1A). Immunoblotting of the hepatocyte extracts
with the phospho-AMPK substrate motif antibody demonstrated
that the antibody readily recognised several protein bands at various
molecular weights in the untreated samples, and overall number and
intensity of the bands were substantially increased upon treatment
(Fig. 1A).
In order to identify the proteins that were immunoreactive with the
phospho-AMPK motif antibody, total hepatocyte extracts (that had
been treated with or without the AMPK activator cocktail) were
immunoprecipitated with the phospho-AMPK substrate motif antibody
or rabbit IgG (non-speciﬁc control) and the resulting immunoprecipi-
tates were subjected to SDS-PAGE, in-gel tryptic digestion followed by
MS/MS analysis. A Coomassie-stained gel of the immunoprecipitates
showed that although several unique (absent in the IgG control) pro-
tein bands were present in the samples immunoprecipitated
with the phospho-AMPK motif antibody, only a small minority were
enriched in the treated samples (indicatedwith asterisk in Fig. 1B). Pos-
sible reasons for such a modest difference between the treated and
the untreated group (as compared to the phospho-AMPK motif
immunoblot of the total extract in Fig. 1A) could be that AMPK-
activator-regulated bands might have been masked by non-speciﬁc
bands or the abundance of the regulated bands was too low to be
detected by Coomassie staining. Another reason could be that as
the phospho-AMPK motif antibody was raised against a short linear
peptide, it will not recognise all the phospho-sites in folded native
proteins.
Tryptic peptides derived from the experiment shown in Fig. 1B were
analysed by LC-MS/MS and the resulting data were searched against the
Swiss-Prot mouse database. To demonstrate consistency and reproduc-
ibility of the analysis a technical replicate (immunoprecipitation plus
LC-MS/MS) using the same hepatocyte lysates was performed (exp1a
and exp1b). A total of 549 proteinswere detected (2 peptidesminimum
with 95% probability) across both runs. After removing proteins present
in the IgG negative control, we performed label-free quantiﬁcation by
total spectral counting. 99 proteins were enriched in the treated versus
untreated samples in the ﬁrst run (exp1a). In the second run (exp1b),
59 enriched proteins were identiﬁed, of which the vast majority
were also present in the ﬁrst run (Fig. 1C). In total, 101 proteins were
enriched in the treated versus untreated samples (Fig. 1C). We then
performed a biological replicate (independent isolation of primary
hepatocytes; 776 proteins detected with 2 peptides minimum and
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Fig. 1.Analysis of phospho-AMPK substratemotif antibody immunoprecipitates byMS/MS. (A, B) Primary hepatocyteswere isolated frommale C57BL/6mice (12-week-old). Hepatocytes
were incubatedwith vehicle or a combination of 0.3mMAICAR and 10 μMA769662 for 45min. (A) Cell lysates (20 μg) were analysed by immunoblotting using the indicated antibodies.
(B) Total cell lysates (2mg)were immunoprecipitated using 1 μg anti-phospho-AMPK-substratemotif (p-AMPKmotif) or non-speciﬁc control rabbit antibody (IgG). Immunoprecipitates
were separated by SDS-PAGE and the gel was stained using colloidal Coomassie. Boxes on the image indicate where gel bands were excised for subsequent sample processing (trypsin
digestion andMS/MS analysis). (C) Samples frompanel Bwere analysed by LC-MS/MS, searched against the Swiss-Protmouse database and the amount of protein detectedwas quantiﬁed
by total spectral counting. 99 proteins were enriched in the stimulated versus basal samples in the ﬁrst run (exp1a) and 59 in the technical replicate using the same starting material
(exp1b) (upper diagram). In total, 101 proteins were enriched in the stimulated versus basal samples (exp1). In a biological replicate of the experiment, 157 proteins were enriched in
the stimulated versus basal samples (exp2). Across both biological replicates, 64 proteins were enriched (lower diagram). (D) Primary hepatocytes were isolated from AMPKα1/α2
liver-speciﬁc knockout mice (KO) and AMPKα1lox/loxα2lox/lox mice (CON) (10-week-old). Plated cells were treated with vehicle or a combination of 0.3 mM AICAR and 10 μM A769662
for 45min. Cell extracts (20 μg)were analysed by immunoblot analysis using the indicated antibodies. (E) Primary hepatocytes from control and AMPKKOmicewere treatedwith vehicle
or a combination of 0.3mMAICAR and 10 μMA769662 for 45min. Total cell lysates (2mg)were immunoprecipitatedusing anti-phospho-AMPKmotif antibody (p-AMPKmotif) or control
rabbit IgG. Immunoprecipitateswere separated by SDS-PAGE and the gelwas stained using colloidal Coomassie. Regions of the gel (analogous to panel B)were excised (image not shown)
for further processing (trypsin digestion andMS/MS analysis). 72 proteinswere enriched upon stimulation in the sample originating fromAMPK KO, and 157 proteins in the sample from
control mouse hepatocytes (CON). 125 proteins were uniquely enriched in the control sample.
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Table 1
List of potential AMPK substrates/targets identiﬁed byMS analysis (Fig. 1B and C). Known
AMPK substrates are highlighted in green. Proteins that did not fulﬁl the criteria of AMPK
dependent regulation (Fig. 1E) are greyed out at the bottom of the list.
Accession Gene name Protein name
Q8CBW3 Abi1 Abl interactor 1
Q8K4G5 Ablim1 Actin-binding LIM protein 1
Q5SWU9 Acaca Acetyl-CoA carboxylase 1
Q8VHH5 Agap3 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3
O08739 Ampd3 AMP deaminase 3
Q3UMR0 Ankrd27 Ankyrin repeat domain-containing protein 27
Q7TPS5 C2cd5 C2 domain-containing protein 5
Q80U49 Cep170b Centrosomal protein of 170 kDa protein B
P59242 Cgn Cingulin
Q68FD5 Cltc Clathrin heavy chain 1
Q3UMF0 Cobll1 Cordon-bleu protein-like 1
Q7TMB8 Cyfip1 Cytoplasmic FMR1-interacting protein 1
P11531 Dmd Dystrophin
E9Q557 Dsp Desmoplakin
Q80TH2 Erbb2ip Protein LAP2
Q3UQN2 Fcho2 FCH domain only protein 2
Q9JI19 Fibp Acidic fibroblast growth factor intracellular-binding protein
Q9Z1S8 Gab2 GRB2-associated-binding protein 2
Q6PAR5 Gapvd1 GTPase-activating protein and VPS9 domain-containing protein 1
Q3UHD2 Gfod1 Glucose-fructose oxidoreductase domain-containing protein 1
Q9R0T8 Ikbke Inhibitor of nuclear factor kappa-B kinase subunit epsilon
A2A7S8 Kiaa1522 Uncharacterized protein KIAA1522
O35071 Kif1c Kinesin-like protein KIF1C
Q8C052 Map1s Microtubule-associated protein 1S
Q60592 Mast2 Microtubule-associated serine/threonine-protein kinase 2
Q6PCP5 Mff Mitochondrial fission factor
Q8R1S4 Mtss1 Metastasis suppressor protein 1
P28660 Nckap1 Nck-associated protein 1
Q9QYF9 Ndrg3 Protein NDRG3
P70313 Nos3 Nitric oxide synthase, endothelial
Q8CI95 Osbpl11 Oxysterol-binding protein-related protein 11
A2A8Z1 Osbpl9 Oxysterol-binding protein-related protein 9
Q3UEI1 Pde4c cAMP-specific 3',5'-cyclic phosphodiesterase 4C
Q69Z38 Peak1 Pseudopodium-enriched atypical kinase 1
Q8BWJ3 Phka2 Phosphorylase b kinase regulatory subunit alpha, liver isoform
Q7TSH2 Phkb Phosphorylase b kinase regulatory subunit beta
Q8K1N2 Phldb2 Pleckstrin homology-like domain family B member 2
Q4VAC9 Plekhg3 Pleckstrin homology domain-containing family G member 3
Q60953 Pml Protein PML
A2AHG0 Prosapip1 ProSAP-interacting protein 1
A3KGS3 Ralgapa2 Ral GTPase-activating protein subunit alpha-2
Q8BQZ4 Ralgapb Ral GTPase-activating protein subunit beta
O89032 Sh3pxd2a SH3 and PX domain-containing protein 2A
O88343 Slc4a4 Electrogenic sodium bicarbonate cotransporter 1
Q99L88 Sntb1 Beta-1-syntrophin
P16546 Sptan1 Spectrin alpha chain, non-erythrocytic 1
Q9D0I4 Stx17 Syntaxin-17
Q8BJS4 Sun2 SUN domain-containing protein 2
Q5F2E8 Taok1 Serine/threonine-protein kinase TAO 1
Q9Z0U1 Tjp2 Tight junction protein ZO-2
Q9EP53 Tsc1 Hamartin
Q61037 Tuberin
P58854 Tubgcp3 Gamma-tubulin complex component 3
Q9QY76 Vapb Vesicle-associated membrane protein-associated protein B
Q8BH57 Wdr48 WD repeat-containing protein 48
P83741 Wnk1 Serine/threonine-protein kinase WNK1
Q8VDZ4 Zdhhc5 Palmitoyltransferase ZDHHC5
Q9R049 Amfr E3 ubiquitin-protein ligase AMFR
Q9DBT5 Ampd2 AMP deaminase 2
P62046 Lrch1 Leucine-rich repeat and calponin homology domain-containing protein 1
O08648 Map3k4 Mitogen-activated protein kinase kinase kinase 4
Q62433 Ndrg1 Protein NDRG1
P33215 Nedd1 Protein NEDD1
P62069 Usp46 Ubiquitin carboxyl-terminal hydrolase 46
Tsc2
982 S. Ducommun et al. / Cellular Signalling 27 (2015) 978–98895% probability) in which 157 proteins were enriched in the treated
versus untreated samples (exp2). Comparing the two biological repli-
cates, we identiﬁed 64 proteins that were enriched in both experiments
(Fig. 1C), two of which are known AMPK substrates, ACC1 and TSC2
(Table 1).
3.2. Detection of AMPK-dependent targets
Given that the AMPK-activatormixturewould produce some degree
of off-target effects [22], wewanted to clarify whether the obtained hits
were truly AMPK-dependent. We therefore analysed samples derived
from hepatocytes genetically lacking both AMPKα-catalytic isoforms
(AMPK KO). As anticipated [18,23], there was no detectable level
of AMPKα proteins in AMPK KO hepatocytes, and most of the
protein bands recognised by the phospho-AMPK motif antibody in the
treated hepatocytes from control mice (AMPKα1lox/loxα2lox/lox) were
absent in activator-treated AMPK KO samples (Fig. 1D). In the AMPK
KO hepatocytes LC-MS/MS analysis identiﬁed 72 proteins which were
enriched in the immunoprecipitates upon stimulation, whereas in thecorresponding sample derived from control hepatocytes there were
157 enriched proteins, 125 of which were unique to the control sample
(Fig. 1E). A largemajority (89% or 57 out of 64 proteins) of the enriched
proteins identiﬁed in the experiments using wild-type hepatocytes
(exp1) were not enriched in the AMPK KO samples, conﬁrming AMPK
dependence (Table 1). In order to determinewhether proteins enriched
in the stimulated samples are likely targets/substrates of AMPK (as
opposed to proteins co-immunoprecipitating with AMPK targets as
binders), we performed bioinformatics analysis using PROSITE (http://
prosite.expasy.org) [24] and screened our hits for the presence of the
AMPK consensus L-X-R-X-X-*S/*T (X represents any amino acid and *
denotes the phosphorylated residue) [16] which the phospho-AMPK
motif antibody is raised against.
3.3. Biochemical validation of cingulin as an AMPK substrate
In our initial screen (exp1a–b) (Fig. 1A–C), MS analysis of tryptic
peptides derived from phospho-AMPK motif antibody immunoprecipi-
tates identiﬁed a phosphopeptide (SQ*SQASLTGLAFMSPSNR; * denotes
phosphorylation) that displays a perfect match with AMPK consensus
sequence (L-X-R-X-X-*S/*T) in the AICAR/A769662-treated samples
(raw data not shown). This peptide is proteotypic to (i.e. a protein-
speciﬁc sequence of) cingulin (residues 130–147 of mouse cingulin), a
protein known to be localised at tight junctions which has also been
shown to interact with microtubules in epithelial and endothelial cells
[25]. Bioinformatic analysis showed that the phosphorylation site
(S137 on human cingulin) and its surrounding residues (that conform
to AMPK consensus) are well conserved inmammals and also in certain
lower vertebrates like African clawed frog (X. laevis) (Fig. 2A). To vali-
date one of the hits using an alternative method, we generated a
phospho-speciﬁc cingulin (S137) antibody. The speciﬁcity of this anti-
body was conﬁrmed by immunoblot analysis using extracts from
COS-1 cells that had been transfected with constructs encoding
FLAG-tagged wild-type or phospho-deﬁcient S137A mutant of
human cingulin (Fig. 2B). We also observed that the phospho-AMPK
motif antibody recognised a band at the molecular weight of cingulin
in the wild-type-expressing cells, which was ablated in extracts from
the phospho-deﬁcient S137A mutant-expressing cells (Fig. 2B). We
then attempted to detect phosphorylation of endogenous S137 (S132
in mouse) phosphorylation of cingulin in primary hepatocytes. Our
phospho-cingulin S137 antibody failed to detect a speciﬁc endogenous
band either by direct immunoblotting or immunoblotting of total
cingulin antibody immunoprecipitates of the extracts. We speculated
that the antibody may not be sensitive enough to detect endogenous
levels of phospho-cingulin, particularly in tissues where expression is
low. Immunoblot analysis of a mouse tissue panel showed that cingulin
expression in the liver was relatively low compared to the testis, pan-
creas and brain (Fig. 2C). We then screened several cell lines (data not
shown) and found that cingulin was abundantly expressed in a
human intestinal cell line (Caco2). Since we experienced that AICAR is
relatively poor activator of AMPK in several of the immortalised cell
lineswe had tested, we stimulated Caco2 cells with a recently identiﬁed
potent and selective AMPK activator (termed 991 or also named ex229)
[26,27]. Phosphorylation of AMPK on Raptorwas increased at 5min and
peaked at 30 min following the treatment, while ACC phosphorylation
was readily saturated at 5 min. In contrast, phosphorylation of endoge-
nous cingulin S137 was transiently (5–15 min) increased (~1.3–1.7-
fold increase over untreated) and was returned to the resting level
30 min following compound treatment (Fig. 2D).
3.4. Tissue expression of MFF splice-variants and identiﬁcation of in vivo
phosphorylation sites on MFF by MS
We next wished to validate whether mitochondrial ﬁssion factor
(MFF) is a genuine AMPK-dependent substrate. Wewere particularly in-
terested inMFF, as AMPK is implicated in controlling energymetabolism
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[1] and also MFF-derived peptides were substantially enriched
in the immunoprecipitates from the AICAR/A769662-treated sam-
ples. In the process of cloning MFF from murine RNA libraries (as
described in the Materials and methods section), and as described
previously [28], we noted the presence of multiple splice-variants
with different expression proﬁles across mouse tissues (Fig. 3A). We
therefore cloned three splice-variants from a mouse RNA library,
which were the predominant variants in the liver (variant 1), testis
(variant 2) and brain (variant 3) (Fig. 3B, Supplementary Fig. 1A and
B). We found that splice variant 1 corresponds to XM_006496573.1
and variant 3 corresponds to NM_029409.2. In variant 2, amino
acids 149–199 of NM_029409.2 were replaced with amino acids
RRQNEIRYE.
To check theMFF variant expression and tissue distribution proﬁle at
the protein levels, a panel of mouse tissue lysates was immunoblotted
using anti-MFF antibody (with or without prior immunoprecipitation
with an anti-MFF antibody) (Fig. 3C). As a positive control, cell extracts
(COS-1) that had been transfected with the coding region of the indi-
vidual 3 variants were immunoblotted in parallel. We observed the
presence of short variants (with gel mobility similar to the size ofB
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in multiple tissues including the heart, muscle, brain, testis and
liver. In the brain and muscle, we observed the largest variant, and
some intermediate variant sizes were observed uniquely in testis
(Fig. 3C). We were particularly interested in the short variant of
MFF (variant 1) as it appeared to match the size of the predominant
variant detected in multiple tissues including the liver. To determine
which residues were phosphorylated in vivo (in intact cells), we
overexpressed FLAG-MFF (variant 1) in COS-1 cells and afﬁnity-
puriﬁed recombinant MFF proteins were subjected to tryptic digestion
followed by MS analysis for phospho-peptide mapping. We obtained
sequence protein coverage of 81% and identiﬁed ﬁve phosphorylated
sites (S48, S129, S131, S146 and S161) (Fig. 3D and Supplemental
Fig. 1C). Among the identiﬁed phosphorylation sites, we noticed that
two phosphorylation sites contain canonical AMPK phosphorylation
motif, S129 on exon 3 (identical on all variants) and S146 at the very
end of exon 3 (where the sequence immediately downstream of the
serine depends on the splice variant) (Fig. 3B). More speciﬁcally, all
variants contain basic residues (R) in −3 and hydrophobic residues
(L) in −5 position, however only variant 1 (but not 2–3) contains a
preferred hydrophobic residue (L) in +4 position.C
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activator treatment
To investigate the phosphorylation of MFF by AMPK, we generated
phospho-speciﬁc antibodies designed to individually detect the candi-
date AMPK sites (S129 (variant 1–3) and S146 (variant 1)). We also
generated another phospho-speciﬁc antibody against S131 (predicted
not be regulated by AMPK based on surrounding peptide sequence) to
demonstrate speciﬁcity of AMPK-dependent phosphorylation of S129
and/or S146 and also to address a concern that phosphorylation of
S131 may interfere detection of S129 phosphorylation. To determine
phospho-site-speciﬁcity of the antibodies, we ectopically expressed
MFF (variant 1) (Fig. 3B) and phospho-deﬁcient alanine mutants
(S129A, S131A, S146A and all combinations thereof) in COS-1 cells
(Fig. 4A) and immunoblot analysis of the extracts was performed. The
pS146 antibody did not recognise any of the mutants where S146 was
mutated to an alanine. On the other hand, both the pS129 and pS131antibodies did not recognise MFF when either S129, S131 or both sites
were mutated to an alanine, probably due to the proximity of the
mutated residue to the phosphorylated serine affecting epitope rec-
ognition by the antibody and/or phosphorylation by the upstream
kinase (Fig. 4A). The phospho-AMPK motif antibody recognised MFF
with the S146A mutation, but not with the S129Amutation, suggesting
that out of the two predicted AMPK motif sites (S129 and S146), phos-
phorylation of MFF at S129 is responsible for the immunoreactivity of
MFF with the phospho-AMPK motif antibody (Fig. 4A).
Because the pS146 antibody was designed to recognise variant 1 in
particular, we needed to verify its recognition of other variants. Overex-
pression of all three MFF variants and their S146A mutants in COS-1
cells showed that the antibody did not recognise variant 2, and only
detected a weak signal from wild-type variant 3 (Fig. 4B). We also
observed that variant 1, in contrast to variants 2 and 3, resolved as a dou-
blet, and that the slower-migrating species disappeared in the S146A
mutant (Fig. 4B). To examine if the doublet was indeed a consequence
985S. Ducommun et al. / Cellular Signalling 27 (2015) 978–988of the phosphorylation event at S146, we immunoblotted puriﬁed FLAG-
tagged MFF (wild-type and S146A mutant) pre-treated with or without
λ-phosphatase. We observed that λ-phosphatase treatment resulted in
the disappearance of the slower-migrating form of the doublet seen in
wild-type MFF, indicating that phosphorylation at S146 is responsible
for the band-shift (Fig. 4C). We next wanted to determine whether
those phosphorylation sites were up-regulated upon AMPK activation
in intact cells. The AMPK activator 991 robustly stimulated AMPK
in COS-1 cells, as judged by phosphorylation of AMPKα and ACC
(Fig. 4D). Treatment with 991 resulted in a modest increase in phos-
phorylation of S129 and S146, but not S131 sites in MFF (variant 1)-
overexpressed COS-1 cells (Fig. 4D). The total MFF immunoblot revealed
that even under treated conditions, the faster-migrating species of MFF
was much more abundant than the slower-migrating species (phos-
phorylated at S146), indicating that the stoichiometry of phosphoryla-
tion at S146 is likely very low (Fig. 4D).A
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analysed by immunoblot analysis using the indicated antibodies. Immunoblots are representat3.6. S129 phosphorylation and S146 phosphorylation of endogenous MFF
were promoted upon AMPK activation
In order to study endogenous phosphorylation ofMFF and its depen-
dence on AMPK, we decided to return to the cell model used for MS
analysis. Primary mouse hepatocytes were treated with the AMPK-
activator mixture (AICAR/A769662), and MFF immunoprecipitates
were subjected to immunoblotting using total and our phospho-
speciﬁc MFF antibodies. We observed that three bands (presumably
splice-variants) were present in primary hepatocytes as detected
with the total MFF antibody (Fig. 5A), which corresponded with
our liver protein expression proﬁle (Fig. 3C). Upon AMPK stimulation,
MFF phosphorylation at S129 was increased, whereas S131 phos-
phorylation was decreased in all three variants. The pS146 antibody
recognised an increase in phosphorylation upon AMPK stimulation
in the shorter variant of MFF. Together with the band-shift seen inC
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variant 1 that we had cloned from mouse liver RNA (Fig. 3B). To deter-
mine if the regulation of phosphorylation on these three sites depends
on activation of AMPK as opposed to an off-target effect of the com-
pounds (AICAR/A769662), we assessed these phosphorylation events
in AMPK KO hepatocytes. We observed that the up-regulation of S129
and S146, as well as the down-regulation of S131 phosphorylation in
response to AICAR/A769662 treatment were substantially eliminated
in the AMPK KO hepatocytes, conﬁrming AMPK dependence of these
phosphorylation events (Fig. 5B).4. Discussion
In order to establish amethodology for identiﬁcation of novel AMPK
targets/substrates, we undertook an MS-based analysis of proteins/
peptides that were isolated from hepatocyte extracts using a phospho-
AMPK substrate motif antibody. We identiﬁed 57 proteins that were
enriched in samples from hepatocytes treated with an AMPK-activator
mixture (AICAR/A769662) (Table 1). AMPK dependence of the peptide
enrichment/phosphorylation was established using AMPK KO hepato-
cytes, even though indirect modulation of phosphorylation (by other ki-
nases/phosphatases) cannot be fully excluded. However, the presence of
established AMPKphosphorylationmotif(s) in the primary sequence en-
hances the likelihood that several of the identiﬁed proteins are direct
AMPK targets. As shown in the current study, additional analyses to con-
ﬁrm endogenous phosphorylation of the hits in intact cells/tissues using
phospho-speciﬁc antibodies (or alternativemethods such as quantitative
MS) and AMPK-deﬁcientmodels with selective AMPK activators provide
more comprehensive and reliable validation. Although our approach is
straightforward and would be useful for identifying a large set of AMPK
targets, there are some limitations. The phospho-AMPK substrate motif
antibody is biased towards proteins/peptides harbouring the motif
which was deﬁned based on the kinase (puriﬁed AMPK) recognising
short, linear peptides in vitro [14,16] and the antibody is raised againstA B
pS129 M
3
2
pS131 M
pS146 M
M
3
2
3
2
3
2
AMPKα1
pS146 MFF
basal
AICAR /
A769662
IP: M
FF
MFF
pS129 MFF
pS131 MFF
37 kDa
25 kDa
37 kDa
25 kDa
37 kDa
25 kDa
w
ith
ou
t l
ys
at
e
n
o
n
-s
pe
cif
ic 
an
tib
od
y
37 kDa
25 kDa
Fig. 5. S129 phosphorylation and S146 phosphorylation of endogenous MFF were up-regulate
week-old). Plated cells were treated with vehicle or a combination of 0.3 mM AICAR and 10 μ
MFF (Santa Cruz) or non-speciﬁc control antibody coupled to NHS-activated Sepharose. Immu
analysed by immunoblotting using the indicated antibodies. (B) Primary hepatocytes were isola
with vehicle or a combination of 0.3 mMAICAR and 10 μMA769662 for 45min. Total cell lysate
antibody coupled to NHS-activated Sepharose. Immunoprecipitates were eluted by boiling i
immunoblotted using the indicated antibodies.a degenerate peptide library containing ﬁxed leucine and arginine resi-
dues at the−5 and−3 positions N-terminal to the phospho-acceptor
(S/T) residue. Therefore, although the antibody may cross-react to
some extent with peptides containing similar side chain properties
(with leucine and arginine at the designated position), it is possible
that only a subset of AMPK substrates that conform to this narrow rec-
ognitionmotif might be identiﬁed by this method. Structural modelling
and site-directed mutagenesis have indicated additional determinants
that, while not present in all previously identiﬁed substrates, improve
the binding/kinetic parameters [12,14]. This may explain in part why
our hit list contains only two known AMPK substrates (ACC1 and
TSC2), although this may also be related to the relative abundance of
known AMPK substrates in hepatocytes.
In our initial screen, we observed enrichment of a phosphopeptide
(SQ*SQASLTGLAFMSPSNR) corresponding to residues 130-147of
mouse cingulin that showed a perfect match with the AMPK consensus
(L-X-R-X-X-*S/*T) in AMPK-activator-treated samples (data not
shown). While we were validating AMPK-dependent cingulin phos-
phorylation (S137 on human cingulin) using a phospho-speciﬁc anti-
body, Yano et al. reported that cingulin is likely a novel AMPK
substrate, and that AMPK-mediated phosphorylation of cingulin pro-
motes association of planar apical microtubules with tight junctions
[29]. Although the work was elegantly performed in terms of cell biolo-
gy, evidence that AMPK phosphorylates cingulin was only derived from
in vitro assay using recombinant preparations. Based on the sequence
analysis of cingulin, they predicted that AMPK might phosphorylate
S137 and S155 (equivalebt to S132 and S150 onmouse cingulin, respec-
tively)) and they concluded that both sites might be phosphorylated by
AMPK based on the ﬁnding that an in-gel detection of phosphoproteins
(AMPK-phosphorylated cingulin) using ﬂuorescent method in wild-
type cingulin was abolished in the double S132A and S150A mutant,
but not in the single mutant. We here provide evidence that endoge-
nous cingulin S137 phosphorylation is transiently increased upon
pharmacological AMPK activation in a human intestinal cell line
(Caco2). This has validated our approach in characterizing the AMPK-basal
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functional analysis by Yano et al. [29]. Given that a phosphopeptide con-
taining S150 of cingulin was not identiﬁed in our screen and the site
does not appear to be a typical AMPK phosphorylation site (SNRST*S,
*putative phosphorylation), we did not study this further. We noticed
that a tight junction protein zonula occludens (ZO)-2, one of the tight
junction proteins known to interact with cingulin [30], was also identi-
ﬁed as a potential AMPK target (Table 1). ZO-2 contains a potential
AMPK site (MRRAA*SRDQL, residue 955–964 of mouse ZO-2). It
would be interesting to determine if ZO-2 is a direct substrate of
AMPK or was identiﬁedmerely by co-precipitation through direct in-
teraction with cingulin.
AMPK is implicated in controlling cellular energy metabolism
throughmodulatingmitochondrial function. For example, AMPK activa-
tion has been reported to increase mitochondrial biogenesis through
phosphorylating PGC-1α [31] or by increasing PGC-1α deacetylation
via an increase in cellular NAD+ content and SIRT1 activity [32]. AMPK
has also been shown to regulate mitophagy via suppression of the
mTOR pathway as well as directly phosphorylating ULK1 [33,34]. Fur-
thermore, it has been reported that treatment of INS-1E pancreatic
β-cells with AICAR protects mitochondria from palmitate-induced frag-
mentation via phosphorylation of Drp1 [35]. MFF is a mitochondrial
outer membrane protein that has been proposed to play a role in the
recruitment of Drp1 (which is a key player in mitochondrial division,
during mitochondrial ﬁssion) [28,36,37]. Thus we were encouraged to
investigate whether MFF is a cellular target of AMPK, as that may reveal
a key role for AMPK in regulatingmitochondrial function via controlling
their dynamics of ﬁssion and fusion upon energy stress. We demon-
strated that three splice-variants of endogenous MFF, present in pri-
mary mouse hepatocytes, were phosphorylated on S129. We also
observed that the shortest variant (variant 1) was phosphorylated
at an additional site (S146) upon AMPK activation. This might be due
to the fact that variants 2–3 do not contain hydrophobic amino acid in
the +4 position (from phospho-acceptor S146 site) (Fig. 3B) that is
commonly seen in well-established AMPK substrates [12,15] and that
also showed strong selectivity in a peptide library approach [16]. How-
ever, we cannot rule out the possibility that the pS146 antibody does
not recognise phosphorylation of S146 in variants 2–3. It would be
worthwhile examining if S146 is indeed phosphorylated and if so,
whether it is increased in an AMPK-dependent mechanism. Whatever
the case, it would be interesting to investigate the impact/role that
AMPK-dependent phosphorylation of MFF plays (and also determine
if there is a variant-speciﬁc role) on mitochondrial architecture and
function. To this effect, one could study the effect of AMPK activation
on mitochondrial morphology and whether expression of phospho-
deﬁcient MFF mutants in a cell system devoid of endogenous MFF
(e.g. by knockout) affects Drp1 recruitment and ultimately fragmenta-
tion of the mitochondria.
5. Conclusions
We report a motif afﬁnity proteomic approach for the discovery of
cellular AMPK targets and validation of two speciﬁc hits of interest
(cingulin and MFF). Although the method has some limitations (as
described above in the Discussion section), by combining geneticmodels
aswell as speciﬁc AMPK activators, this approach can become a powerful
and reliable screeningmethod that enables researchers to identify a large
set of potential AMPK targets in various cells/tissues.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2015.02.008.
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